An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Disease risks scored according to the revised International Prognostic Scoring System (IPSS-R) and presence of comorbidity graded according to the HCT Comorbidity Index (HCT-CI) were recognized as relevant clinical variables for HSCT eligibility. Fit patients with higher-risk IPSS-R and those with lower-risk IPSS-R with poor-risk genetic features, profound cytopenias, and high transfusion burden are candidates for HSCT. Patients with a very high MDS transplantation risk score, based on combination of advanced age, high HCT-CI, very poor-risk cytogenetic and molecular features, and high IPSS-R score have a low chance of cure with standard HSCT and consideration should be given to treating these patients in investigational studies. Cytoreductive therapy prior to HSCT is advised for patients with ≥10% bone marrow myeloblasts. Evidence from prospective randomized clinical trials does not provide support for specific recommendations on the optimal high intensity conditioning regimen. For patients with contraindications to high-intensity preparative regimens, reduced intensity conditioning should be considered. Optimal timing of HSCT requires careful evaluation of the available effective nontransplant strategies. Prophylactic donor lymphocyte infusion (DLI) strategies are recommended in patients at high risk of relapse after HSCT. Immune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after HSCT.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML : recommendations from an international expert panel / T. de Witte, D. Bowen, M. Robin, L. Malcovati, D. Niederwieser, I. Yakoub Agha, G.J. Mufti, P. Fenaux, G. Sanz, R. Martino, E.P. Alessandrino, F. Onida, A. Symeonidis, J. Passweg, G. Kobbe, A. Ganser, U. Platzbecker, J. Finke, M. van Gelder, A.A. van de Loosdrecht, P. Ljungman, R. Stauder, L. Volin, H.J. Deeg, C. Cutler, W. Saber, R. Champlin, S. Giralt, C. Anasetti, N. Kröger. - In: BLOOD. - ISSN 0006-4971. - 129:13(2017 Mar 30), pp. 1753-1762. [10.1182/blood-2016-06-724500]

Allogeneic hematopoietic stem cell transplantation for MDS and CMML : recommendations from an international expert panel

F. Onida;
2017-03-30

Abstract

An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Disease risks scored according to the revised International Prognostic Scoring System (IPSS-R) and presence of comorbidity graded according to the HCT Comorbidity Index (HCT-CI) were recognized as relevant clinical variables for HSCT eligibility. Fit patients with higher-risk IPSS-R and those with lower-risk IPSS-R with poor-risk genetic features, profound cytopenias, and high transfusion burden are candidates for HSCT. Patients with a very high MDS transplantation risk score, based on combination of advanced age, high HCT-CI, very poor-risk cytogenetic and molecular features, and high IPSS-R score have a low chance of cure with standard HSCT and consideration should be given to treating these patients in investigational studies. Cytoreductive therapy prior to HSCT is advised for patients with ≥10% bone marrow myeloblasts. Evidence from prospective randomized clinical trials does not provide support for specific recommendations on the optimal high intensity conditioning regimen. For patients with contraindications to high-intensity preparative regimens, reduced intensity conditioning should be considered. Optimal timing of HSCT requires careful evaluation of the available effective nontransplant strategies. Prophylactic donor lymphocyte infusion (DLI) strategies are recommended in patients at high risk of relapse after HSCT. Immune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after HSCT.
Acute myeloid-leukemia; bone-marrow-transplantation; prognostic scoring system; risk myelodysplastic syndrome; identical sibling donors; chronic myelomonocytic leukemia; somatic mutations identify; acute leukemia; graft-versus-leukemia; monosomal karyotype
Settore MED/15 - Malattie del Sangue
BLOOD
Article (author)
File in questo prodotto:
File Dimensione Formato  
1753.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 738.94 kB
Formato Adobe PDF
738.94 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/514042
Citazioni
  • ???jsp.display-item.citation.pmc??? 66
  • Scopus 175
  • ???jsp.display-item.citation.isi??? 165
social impact